Skip to main content
ZVRA
NASDAQ Life Sciences

CHMP Rejects EU Marketing Application for Arimoclomol, EC Decision Due Within 67 Days

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$10.1
Mkt Cap
$664.072M
52W Low
$8.01
52W High
$15.035
52W Position info
26% above low
Off High info
33% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ZVRA sits 26% above its 52-week low of $8.01.

Summary

The EMA's CHMP adopted a negative opinion on Zevra's EU marketing application for arimoclomol in Niemann-Pick disease type C, a material setback to the company's planned European expansion. The European Commission now has 67 days to issue its final decision, which will determine whether the application can proceed to authorization. Zevra will keep its expanded access program running for eligible patients, but that provides no commercial EU authorization. The company's Q3 2026 filing already flagged the European arimoclomol application as in re-examination, so this confirms the review has gone against Zevra at the committee stage. The U.S. business is carrying the story financially — Q3 revenue of $37.8 million, up 45%, with $270.9 million in cash and no debt — so the hit is to the EU growth option rather than near-term liquidity. Watch the European Commission's final ruling within 67 days.

At the time of this announcement, ZVRA was trading at $10.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $664.1M. The 52-week trading range was $8.01 to $15.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

ZVRA - Latest Insights

ZVRA
Nov 03, 2026, 5:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $9.02 info
Change: -$1.48 (-14%) info
Market Cap: $540.302M info
ZVRA
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.26
Real-time Price: $9.02 info
Change: -$1.24 (-12%) info
Market Cap: $540.302M info
ZVRA
Aug 05, 2026, 5:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $9.02 info
Change: -$1.48 (-14%) info
Market Cap: $540.302M info
ZVRA
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $9.02 info
Change: -$1.58 (-15%) info
Market Cap: $540.302M info
ZVRA
Jun 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.42
Real-time Price: $9.02 info
Change: -$3.40 (-27%) info
Market Cap: $540.302M info